Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Olverembatinib by Ascentage Pharma Group International for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia): Likelihood of Approval
Olverembatinib is under clinical development by Ascentage Pharma Group International and currently in Phase III for Chronic Myelocytic Leukemia (CML,...
Olverembatinib by Ascentage Pharma Group International for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Olverembatinib is under clinical development by Ascentage Pharma Group International and currently in Phase II for Acute Myelocytic Leukemia (AML,...
Olverembatinib by Ascentage Pharma Group International for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Olverembatinib is under clinical development by Ascentage Pharma Group International and currently in Phase II for Acute Lymphocytic Leukemia (ALL,...